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JPHCOPH Examines Consistency-ensured Parametric Tests for
Critical Events of Composite Endpoints
December 18, 2017
Dr. Mohammad Huque, Adjunct Professor of Biostatistics in the Jiann-Ping Hsu College of
Public Health at Georgia Southern University is the lead author of “Consistency-ensured
Parametric Tests for Critical Events of Composite Endpoints,” recently published in The
Journal of Biopharmaceutical Statistics. Composite endpoints (CEs) are commonly used in
clinical trials when clinically important events are rare or when the disease is multifaceted.
However, components of a CE often differ markedly in their clinical importance. The overall
treatment effect on the composite can be driven by less-important, yet more frequently
occurring, components, with no effects on some clinically important components. These
situations create difficulties in interpreting the results of the CE. The literature has proposed
several approaches for handling these conditions, for example, by setting requirements on
the results of the clinically important components. However, for a rare event, it can be
difficult to draw an appropriate conclusion about its contribution to the overall result of the
composite. Here, we propose combining clinically important components to jointly increase their power and to
require that their findings meet a prespecified level of evidence, called the consistency criterion. With the increase
in power, the study can then be designed with the objectives of establishing efficacy for the composite and/or for
the subset of clinically critical components. In this regard, we introduce multiple testing strategies, which account
for the consistency requirement and for the correlation between these two endpoints. We illustrate the
methodology using the PROactive trial.
Dr. Huque is a Fellow of the American Statistical Association and recently retired after a long career as an applied
statistician in the Center for Drug Evaluation and Research at the Food and Drug Association. The Journal of
Biopharmaceutical Statistics was founded in 1991 by Dr. Karl E. Peace, who was its Editor-in-Chief for the first 10
years of its existence.
Posted in Biostatistics, JPHCOPH, JPHCOPH
Share:
JPHCOPH Examines Test Strategies of Treatment Efficacy in
Noninferiority Clinical Trials
December 18, 2017
Dr. Mohammad Huque, Adjunct Professor of Biostatistics in the Jiann-Ping Hsu College of
Public Health Georgia Southern University is the lead author of “Consistency Ensured Test
Strategies for Supportive Evidence of Treatment Efficacy in Noninferiority Clinical Trials,”
recently published in The Journal of Biopharmaceutical Statistics. Noninferiority (NI) clinical
trials are designed to demonstrate that a new treatment is not unacceptably worse than an
active control on a clinically meaningful endpoint. While such an endpoint can be of any
type, the focus of this manuscript is on the binary-type endpoint. Examples of this endpoint
can be clinical cure endpoint for patients with bacterial diseases or based on a pre-
specified virological threshold for viral diseases. However, in addition to assessing such a
binary endpoint for the NI comparison, the trial may also evaluate a second clinically
relevant endpoint for providing additional support to the evidence of the designated primary
endpoint. Specifically, if the trial is successful in demonstrating statistical significance on
the first endpoint, then observing at least a positive trend in efficacy on the second endpoint may provide
additional supportive evidence of efficacy. The second endpoint can be a time-to-event type endpoint, such as
time-to-symptom resolution (TSR) or time to all-cause mortality for infectious disease trials, time-to-wound closure
for wound healing trials, or other endpoints. We propose two consistency ensured test strategies for the two
hypotheses of a trial, one associated with the binary endpoint and the other with the second endpoint, both with
the objective of drawing inference regarding the efficacy of the new treatment based on findings from testing the
two hypotheses. A key feature of these test strategies is that basically it does not require multiplicity adjustment of
the significance levels. We conclude with general discussion of the testing methods and possible applications to
unmet medical need trials.
Dr. Huque is a Fellow of the American Statistical Association and recently retired after a long career as an applied
statistician in the Center for Drug Evaluation and Research at the Food and Drug Association. The Journal of
Biopharmaceutical Statistics was founded in 1991 by Dr. Karl E. Peace, who was its Editor-in-Chief for the first 10
years of its existence.
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